References
- Asher I. ISAAC International Study of Asthma and Allergies in Childhood. Pediatr Pulmonol 2007;42:100-10
- Jaen A, Ferrer A, Ormaza I, et al. Prevalence of chronic bronchitis, asthma and airflow limitation in an urban-industrial area of Catalonia. Arch Bronconeumol 1999;35:122-8
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. NIH publication number 95-3659. http://www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=1562 [Last accessed 15 October 2010]
- Domingo Ch, Ortún V. Chronic saturation of emergency departments: They should not be flooded by patients with chronic diseases. Arch Bronconeumol 2006;42:257-9
- Domingo Ch, Moreno A, Amengual MJ, et al. Twelve years’ experience with methotrexate for GINA treatment step 5 asthma patients. Curr Med Res Opin 2008;25:367-74
- Domingo C. Effectiveness and efficiency of an outpatient clinic for corticosteroid-dependent asthmatics. Arch Bronconeumol 2001;37:274-80
- International Consensus Report on diagnosis and treatment of asthma. National Heart, Lung and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication number 92-3091, March 1992. Eur Respir J 1992;5:601-41
- GEMA 2009. Guía Española para el Manejo del Asma (GEMA). http://www.gemasma.com/descargas/GEMA%202009.pdf [Last accessed 15 October 2010]
- Comet R, Domingo C, Larrosa M, et al. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Respir Med 2006;100:411-19
- Domingo Ch, Pacheco A, Hinojosa M, et al. The relevance of IgE in the pathogenesis of allergy: The effect of an anti-IgE drug in asthma and other diseases. Recent Patents Inflamm Allergy Drug Discov 2007;1:151-64
- Roca J, Sanchis J, Agusti-Vidal A, et al. Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir 1986;22:217-24
- Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma and Immunology/American college of Allergy, Asthma and immunology joint task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120:1373-7
- Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009;103:1725-31
- Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;1365:1-10
- Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008;102:1371-8
- Pacheco-Galvan A, Hinojosa-Macias M, Hurtado-Barbudo B, et al. Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab. Med Clin (Barc) 2009;133:460-3 (abstract in English)
- Liebhaber M, Dyer Z. Home therapy with subcutaneous anti-immunoglobulin-E antibody – omalizumab in 25 patients with immunoglobulin-E-mediated (allergic) asthma. J Asthma 2007;44:195-6